Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2022

Association between hospital private equity acquisition and
outcomes of acute medical conditions among Medicare
beneficiaries
Marcelo Cerullo
Kelly Yang
Karen E. Joynt Maddox
Ryan C. McDevitt
James M. Roberts

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Marcelo Cerullo, Kelly Yang, Karen E. Joynt Maddox, Ryan C. McDevitt, James M. Roberts, and Anaeze C.
Offodile

Original Investigation | Health Policy

Association Between Hospital Private Equity Acquisition and Outcomes
of Acute Medical Conditions Among Medicare Beneficiaries
Marcelo Cerullo, MD, MPH; Kelly Yang, MA; Karen E. Joynt Maddox, MD, MPH; Ryan C. McDevitt, PhD; James W. Roberts, PhD; Anaeze C. Offodile 2nd, MD, MPH

Abstract

Key Points

IMPORTANCE As private equity (PE) acquisitions of short-term acute care hospitals (ACHs)
continue, their impact on the care of medically vulnerable older adults remains largely unexplored.
OBJECTIVE To investigate the association between PE acquisition of ACHs and access to care,
patient outcomes, and spending among Medicare beneficiaries hospitalized with acute medical
conditions.

Question What is the association
between private equity (PE) acquisition
of short-term acute care hospitals and
measures of comorbidity, mortality,
readmission, length of stay, and
spending among Medicare beneficiaries
admitted to the hospital with 1 of 5 acute

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study used a generalized difference-

medical conditions?

in-differences approach to compare 21 091 222 patients admitted to PE-acquired vs non–PE-acquired

Findings In this cross-sectional study of

short-term ACHs between January 1, 2001, and December 31, 2018, at least 3 years before to 3 years

more than 21 million Medicare

after PE acquisition. The analysis was conducted between December 28, 2020, and February 1,

beneficiaries with 5 different acute

2022. Differences were estimated using both facility and hospital service area fixed effects. To assess

medical conditions who were

the robustness of findings, regressions were reestimated after including fixed effects of patient

hospitalized at short-term acute care

county of origin to account for geographic differences in underlying health risks. Two subset analyses

hospitals, PE acquisition was associated

were also conducted: (1) an analysis including only hospitals in hospital referral regions with at least

with significantly lower inpatient

1 PE acquisition and (2) an analysis stratified by participation in the Hospital Corporation of America

mortality (−1.1 percentage points) and

2006 acquisition. The study included Medicare beneficiaries 66 years and older who were

lower 30-day mortality (−1.4 percentage

hospitalized with 1 of 5 acute medical conditions: acute myocardial infarction (AMI), acute stroke,

points) among patients admitted with

chronic obstructive pulmonary disease exacerbation, congestive heart failure exacerbation, and

acute myocardial infarction. However,

pneumonia.

PE acquisition was not associated with
significant differences in other
dimensions of quality and spending or

EXPOSURES Acquisition of hospitals by PE firms.

with differences across other medical

MAIN OUTCOMES AND MEASURES Comorbidity burden (measured by Elixhauser comorbidity
score), hospital length of stay, in-hospital mortality, 30-day mortality, 30-day readmission, and
30-day episode payments.

conditions.
Meaning The study’s findings suggest
that PE acquisition has mixed
consequences for patient-level

RESULTS Among 21 091 222 total Medicare beneficiaries admitted to ACHs between 2001 and
2018, 20 431 486 patients received care at non–PE-acquired hospitals, and 659 736 received care at
PE-acquired hospitals. Across all admissions, the mean (SD) age was 79.45 (7.95) years; 11 727 439
patients (55.6%) were male, and 4 550 012 patients (21.6%) had dual insurance; 2 996 560 (14.2%)
patients were members of racial or ethnic minority groups, including 2 085 128 [9.9%] Black and

outcomes overall but is associated with
moderate and consistent improvement
in mortality among Medicare
beneficiaries hospitalized with acute
myocardial infarction.

371 648 [1.8%] Hispanic; 18 094 662 patients (85.8%) were White. Overall, 3 083 760 patients
(14.6%) were hospitalized with AMI, 2 835 777 (13.4%) with acute stroke, 3 674 477 (17.4%) with
chronic obstructive pulmonary disease exacerbation, 5 868 034 (27.8%) with congestive heart
failure exacerbation, and 5 629 174 (26.7%) with pneumonia. Comorbidity burden decreased slightly
among patients admitted with acute stroke (difference, −0.04 SDs; 95% CI, −0.004 to −0.07 SDs)
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at acquired hospitals compared with nonacquired hospitals but was unchanged across the other 4
conditions. Among patients with AMI, a greater decrease in in-hospital mortality was observed in
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Abstract (continued)

PE-acquired hospitals compared with non–PE-acquired hospitals (difference, −1.14 percentage
points, 95% CI, −1.86 to −0.42 percentage points). In addition, a greater decrease in 30-day mortality
(difference, −1.41 percentage points; 95% CI, −2.26 to −0.56 percentage points) was found at
acquired vs nonacquired hospitals. However, 30-day spending and readmission rates remained
unchanged across all conditions. The extent and directionality of estimates were preserved across all
robustness assessments and subset analyses.
CONCLUSIONS AND RELEVANCE In this cross-sectional study using a difference-in-differences
approach, PE acquisition had no substantial association with the patient-level outcomes examined,
although it was associated with a moderate improvement in mortality among Medicare beneficiaries
hospitalized with AMI.
JAMA Network Open. 2022;5(4):e229581. doi:10.1001/jamanetworkopen.2022.9581

Introduction
Private equity (PE) participation in the health care sector has increased over the past 20 years,1-3 with
approximately one-half of these transactions occurring in the care delivery sector (physicians,
hospitals, and nursing homes).4 Acute care hospitals (ACHs) are particularly attractive to PE firms;
approximately 11% of all nongovernmental hospital discharges in 2017 were from a facility with a
history of PE ownership.5 Private equity firms’ sustained interest in hospitals likely reflects several
factors: (1) perceived inefficiencies that provide opportunities to improve operations,2,6 (2) an aging
population that will require more acute care services,7,8 and (3) fragmented hospital markets that
make horizontal consolidation a possible way to increase negotiating power over payers.9-11 These
for-profit incentives have raised concerns about their consequences for the provision of health care
services and the patient-practitioner relationship. The American College of Physicians recently
disseminated a position paper calling for greater regulatory transparency and “longitudinal research
on the effect of private equity investment on physicians’ clinical decision making, health care prices,
access, and patient care, including the characteristics of models that may have adverse or positive
effects on the quality and cost of care and the patient-physician relationship.”12
Recent work by Gupta et al13 estimated that PE ownership of nursing homes increased shortterm mortality among Medicare patients by 10%, with concomitant reductions in other measures of
patient well-being. In contrast, Braun et al14 estimated that, despite no consistent impact for
spending or procedural volume, prices paid to dermatology practices increased by 3% to 5% after PE
acquisition. However, short-term ACHs differ markedly from both of these subsectors. Despite
substantial interest from policy makers noted in the Medicare Payment Advisory Commission’s June
2021 report,15 few studies have analyzed the association of PE acquisitions of ACHs with spending
and clinical outcomes. Bruch et al11 identified modest but statistically significant improvements in
risk-adjusted hospital-level quality measures for acute myocardial infarction (AMI) and pneumonia
using data collected through the Centers for Medicare & Medicaid Services Hospital Compare
program. The inconclusive findings of studies that have used aggregate quality measures and costto-charge ratios suggest the need for patient-level investigations to understand whether patient
selection and/or differences in clinical practice bias are associated with changes in outcomes.
To address this knowledge gap, we examined the association between PE acquisition of shortterm ACHs and outcomes among Medicare beneficiaries over an 18-year period using a difference-indifferences framework. We specifically sought to quantify the association of PE acquisitions using 6
important measures that encompass overall patient case mix and hospital clinical performance:
comorbidity burden, inpatient mortality, 30-day mortality, 30-day readmission, inpatient length of
stay (LOS), and 30-day episode spending.16 We examined this association across 5 common medical
conditions: AMI, acute stroke, chronic obstructive pulmonary disease (COPD), congestive heart
JAMA Network Open. 2022;5(4):e229581. doi:10.1001/jamanetworkopen.2022.9581 (Reprinted)
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failure (CHF), and pneumonia. These 5 conditions account for a substantial portion of nonelective
admissions, both broadly and among Medicare beneficiaries in particular.17,18

Methods
Study Population
We used the 100% Centers for Medicare & Medicaid Services standard analytic files and enrollment
database to identify Medicare fee-for-service beneficiaries hospitalized between January 1, 2001,
and December 31, 2018. The analysis was conducted between December 28, 2020, and February 1,
2022. This study was approved by the institutional review board of Duke University Medical Center.
Informed consent was waived due to the deidentified nature of the data. This study followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline for cross-sectional studies.19
We identified patients 66 years and older who were admitted via the emergency department
with a principal diagnosis of 1 of the following 5 conditions: AMI, acute stroke, CHF exacerbation,
COPD exacerbation, and pneumonia. Medical conditions were identified using diagnostic codes from
the International Classification of Diseases, Ninth Revision, and the International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision (eTable 1 in the Supplement).
These cohorts were considered independently, and previously published protocols to classify index
admissions and readmissions were used.20 Admissions classified as elective were excluded. To
ensure that patients had at least 1 year of Medicare enrollment before hospital admission, those 65
years and younger were excluded.
Demographic information, including age, sex, race and ethnicity, and entitlement type, were
abstracted from the beneficiary summary file. Comorbidities were identified using all admissions in
the year before and up to the index admission and were summarized using Elixhauser comorbidity
scores21,22; this approach was used because Centers for Medicare & Medicaid Services hierarchical
conditions category risk scores were first implemented in 2004,23 and our period of interest included
the years before its implementation.24

Definition of Outcomes
Primary outcomes evaluated at the patient level included comorbidity burden (measured by
Elixhauser comorbidity scores), in-hospital mortality, 30-day mortality (death within 30 days of
admission), hospital LOS, 30-day all-cause readmission, and total inpatient spending per 30-day care
episode. Hospital LOS and 30-day all-cause readmission were conditional on being discharged alive.

Hospital Characteristics
Hospitals acquired by PE firms via primary or add-on leveraged buyout between 2003 and 2015 were
identified using previously described methods.5 These hospitals were linked to financial data
reported on Healthcare Cost Report Information System–Medicare Cost Reports and geographic
location information (eg, physical address) contained in the Medicare provider of services files to
determine patient county of origin, hospital service area (HSA), and hospital referral region. All
non–federally owned hospitals with noncritical access that were not acquired by PE firms during this
period were considered potential controls. Critical access hospitals were excluded because of their
small inpatient bed count (<25 beds) and exemption from traditional reimbursement (ie, cost
reimbursement rather than a prospective payment system) and fee structures. Hospital-level factors
included size (<100 beds, 100-299 beds, or ⱖ300 beds), ownership type (for-profit, nonprofit, or
government-run), teaching status (teaching vs nonteaching), medical school affiliation (affiliated vs
unaffiliated), and core-based statistical area designation (metropolitan, micropolitan, or outside of a
core-based statistical area designation).
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Statistical Analysis
The association of PE acquisition with patient outcomes was estimated using a generalized
difference-in-differences approach covering a minimum of 3 years in the preacquisition (baseline)
period and a 3-year limitation in the postacquisition period, using the interaction term between an
indicator for PE acquisition and the 3-year period after acquisition. Our postacquisition horizon of 3
years was chosen to match the exit strategies (eg, divestment or secondary buyouts by another PE
firm) commonly used by PE firms, which are not readily disclosed or identifiable in the public domain.
The following patient-level covariates were included in our model: age, sex, race and ethnicity
(Asian or Pacific Islander, Black, Hispanic, North American Native, White, or other or unknown race
and/or ethnicity), dual eligibility, type of entitlement (age, disability, or end-stage kidney disease),
admission type (emergency or urgent), hospitalization within the previous year, and Elixhauser
comorbidity score. Hospital fixed effects were included to account for time-invariant hospitalspecific unobserved confounders; fixed effects for HSA by year were included to control for regionspecific time trends, which encompassed either changes in overall hospital quality, legislation, or
treatment standards introduced by clinical guidelines. Binary outcomes were estimated using a linear
probability model, and continuous outcomes (LOS and total payments) were log-transformed and
right winsorized at the 99th percentile to mitigate skewness (ie, values >99th percentile were set to
the value of the 99th percentile).
In this specification, the difference-in-differences estimator can be interpreted as the difference
in outcomes among patients within hospitals after PE acquisition, after adjustment for patient-level
factors. Standard errors were clustered at the hospital level. We controlled for false discovery rate in
the primary analyses using the Benjamini and Hochberg method, and we reported corrected P values
alongside uncorrected P values.25 The full model specification is provided in eMethods in the
Supplement, and results of the preparatory analyses using an event study framework to examine
parallel trends are available in eFigures 1 to 6 in the Supplement. All analyses were conducted using
Stata SE software, version 16.0 (StataCorp LLC), and a 2-tailed P < .05 was considered statistically
significant.
Although our model specification allowed for a conservative estimate of the consequences of
PE acquisition at the patient level, it may not have fully accounted for patient selection based on
unobservable factors. In other words, differences detected within hospitals after PE acquisition may,
in fact, have been associated with unobserved differences among patients admitted to those
hospitals after acquisition. Therefore, we also considered an alternative specification that included
fixed effects for a patient’s county of origin to account for geographic variation in health care access,
social factors associated with health, and demographic factors that might have been associated with
any noted differences in outcomes.26-28
We further examined 2 alternative specifications of the study cohort to assess whether the
directionality of our estimates was consistent. First, because PE acquisitions are concentrated in
specific geographic regions (eg, southeastern US) based on published literature,5 we repeated our
analyses after restricting the sample to hospital referral regions in which at least 1 PE acquisition had
occurred. Second, we stratified the sample of PE-acquired hospitals into 2 groups: members of the
Hospital Corporation of America (HCA) health care system and all other hospitals. This decision was
motivated by the fact that the 2006 HCA leveraged buyout by PE firms accounted for more than
50% of the hospitals in the sample, and stratification by HCA status was consistent with the
approach used in recent PE scholarship.11 We repeated each generalized difference-in-differences
model and excluded, in turn, HCA hospitals and non-HCA hospitals from the treatment group.

Results
After accounting for observations in all years of our study period (2001-2018), a total of 21 091 222
care episodes were included across 3559 hospitals (257 of which were acquired by PE firms and had
at least 3 years of data before and after acquisition; 11 hospitals closed within 3 years after
JAMA Network Open. 2022;5(4):e229581. doi:10.1001/jamanetworkopen.2022.9581 (Reprinted)
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acquisition). Overall, 20 431 486 episodes occurred at non–PE-acquired hospitals, and 659 736
occurred at PE-acquired hospitals. Across all admissions, the mean (SD) age was 79.45 (7.95) years;
11 727 439 patients (55.6%) were male, 9 363 783 (44.4%) were female, and 4 550 012 (21.6%) had
dual insurance. Among the total of 21 091 222 patients, 2 996 560 (14.2%) were members of racial
and ethnic minority groups (246 014 [1.2%] were Asian or Pacific Islander, 2 085 128 [9.9%] were
Black, 371 648 [1.8%] were Hispanic, 73 348 [0.3%] were North American Native, and 220 422
[1.0%] were of unknown race and/or ethnicity), and 18 094 662 patients (85.8%) were White. A total
of 3 083 760 patients (14.6%) were admitted with AMI, 2 835 777 (13.4%) with acute stroke,
5 868 034 (27.8%) with CHF exacerbation, 3 674 477 (17.4%) with COPD exacerbation, and 5 629 174
(26.7%) with pneumonia. Patient-level summary statistics across hospitals acquired and never
acquired by PE firms are provided in the Table. Patient-level summary statistics across each of the 5
conditions (with data on age, sex, race and ethnicity, and Elixhauser comorbidity scores) at the
beginning and end of our study period and annual rates for each outcome studied (in-hospital
mortality, 30-day mortality, 30-day readmission, LOS, and spending) are provided in eTable 2 in the
Supplement. Of note, unadjusted LOS and in-hospital mortality decreased across the study period for
all 5 conditions. The proportion of patients receiving treatment across hospital types, including
teaching vs nonteaching, for-profit vs nonprofit, and metropolitan vs micropolitan status are
available in eTable 3 in the Supplement.

Table. Characteristics of Patients Treated in Hospitals Acquired and Not Acquired by PE Firms
No. (%)
Characteristic

Non–PE-acquired hospitals

PE-acquired hospitals

Total patients, No.

20 431 486

659 736

Female

9 074 055 (44.4)

289 728 (43.9)

Male

11 357 431 (55.6)

370 008 (56.1)

80.0 (8.0)

79.0 (8.0)

Racial and ethnic minority groupsb

2 888 883 (14.2)

107 677 (16.3)

White

17 542 603 (85.8)

552 059 (83.7)

2.08 (2.95)

2.16 (3.00)

AMI

2 990 957 (14.6)

92 803 (14.1)

Acute stroke

2 756 284 (13.5)

79 493 (12.0)

CHF exacerbation

5 674 250 (27.8)

193 784 (29.4)

COPD exacerbation

3 556 147 (17.4)

118 330 (17.9)

Pneumonia

5 453 848 (26.7)

175 326 (26.6)

<100 beds

2 072 976 (10.1)

41 784 (6.3)

100-299 beds

7 827 556 (38.3)

342 686 (51.9)

≥300 beds

10 530 954 (51.5)

275 266 (41.7)

Teaching

9 739 995 (47.7)

222 070 (33.7)

Nonteaching

10 691 491 (52.3)

437 666 (66.3)

For-profit

1 677 888 (8.2)

463 867 (70.3)

Nonprofit

15 955 329 (78.1)

157 882 (23.9)

Government-run

2 798 269 (13.7)

37 987 (5.8)

Sex

Age, mean (SD), y
Race and ethnicitya

Elixhauser comorbidity score, mean (SD)
Condition

Hospital size

Hospital teaching status

Hospital ownership

Core-based statistical area designation
Metropolitan

17 358 393 (85.0)

596 186 (90.4)

Micropolitan

2 360 853 (11.6)

49 847 (7.6)

Outside of core-based statistical area
designation

712 240 (3.5)

13 703 (2.1)
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Patient Selection and Clinical Outcomes After PE Acquisition
The age at admission decreased slightly among patients hospitalized with pneumonia at PE-acquired
hospitals compared with non–PE-acquired hospitals (difference, −0.20 SDs; 95% CI. −0.34 to −0.06
SDs; uncorrected P = .006; corrected P = .07) but was unchanged for the 4 other conditions
examined. After PE acquisition, comorbidity burden decreased slightly among patients admitted
with acute stroke (difference, −0.04 SDs; 95% CI, −0.004 to −0.07 SDs; uncorrected P = .03;
corrected P = .24) at acquired hospitals compared with nonacquired hospitals but was unchanged
across the other 4 conditions (Figure 1).
Among patients admitted with AMI, a greater decrease in in-hospital mortality was observed
among PE-acquired hospitals compared with non–PE-acquired hospitals (difference, −1.14
percentage points; 95% CI, −1.86 to −0.42 percentage points; uncorrected P = .002; corrected
P = .03). In addition, after PE acquisition, a −1.41 percentage point (95% CI, −2.26 to −0.56
percentage points; uncorrected P = .001; corrected P = .03) greater decrease in 30-day mortality
was found at acquired hospitals compared with nonacquired hospitals. For the 4 other conditions
examined, there were no differences in in-hospital mortality or 30-day mortality after PE acquisition.
No differences in LOS were found among patients hospitalized with AMI, acute stroke, CHF, or
pneumonia; patients admitted with COPD exacerbation had slightly shorter adjusted LOS after PE
acquisition (difference, −2.34%; 95% CI, −4.52% to −0.15%; uncorrected P = .04; corrected P = .25),
although this difference was not statistically significant after adjustment for false discovery rate. No

Figure 1. Difference-in-Differences Estimates for Primary Outcomes Across All 5 Medical Conditions
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differences in 30-day readmission and 30-day episode spending across all 5 conditions were noted
(Figure 1).

Robustness Assessments and Subset Analyses
When fixed effects for beneficiary county of residence were included in addition to hospital fixed
effects and hospital HSA-year fixed effects, difference-in-differences estimates of changes in
in-hospital mortality (difference, −1.14 percentage points; 95% CI, −1.86 to −0.42 percentage points)
and 30-day mortality (difference, −1.41 percentage points; 95% CI, −2.26 to −0.55 percentage points)
among patients with AMI were consistent with the analysis using only hospital fixed effects and
hospital HSA-year fixed effects (Figure 2). Moreover, when year fixed effects were included in lieu of
hospital HSA-year fixed effects, difference-in-differences estimates among patients admitted with
AMI were consistent with those obtained using HSA-year fixed effects; specifically, decreases of 0.74
percentage points (95% CI, −1.19 to −0.29 percentage points) in in-hospital mortality and 0.94
percentage points (95% CI, −1.51 to −0.37 percentage points) in 30-day mortality were observed.
Hospital LOS among patients admitted with COPD exacerbation was similarly shorter (difference,
−1.88%; 95% CI, −3.40% to −0.33%), although the clinical importance of this was not clear.
After restricting the patient cohort to those who received treatment at hospitals in hospital
referral regions with at least 1 PE acquisition, patients admitted with AMI had a greater decrease in
in-hospital mortality (difference, −1.12 percentage points; 95% CI, −1.89 to −0.45 percentage points)
and 30-day mortality (difference, −1.41 percentage points; 95% CI, −2.26 to −0.57 percentage points)

Figure 2. Difference-in-Differences Estimates After Including Fixed Effects of Patient County
A Elixhauser comorbidity score
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after PE acquisition. In addition, LOS among patients admitted with COPD exacerbation similarly
decreased (difference, −2.43%; 95% CI, −4.57% to −0.30%), although the extent of the estimate was
small (eFigure 7 in the Supplement).
After partitioning hospitals based on whether they were part of the 2006 HCA acquisition, the
directionality of significant findings remained consistent. Among HCA hospitals, patients with AMI
experienced a greater decrease in in-hospital mortality (difference, −1.33 percentage points; 95% CI,
−2.19 to −0.47 percentage points) and 30-day mortality (difference, −1.40 percentage points; 95%
CI, −2.39 to −0.40 percentage points). Estimates for these 2 outcomes in non-HCA hospitals were
similar in extent but not statistically significant (AMI in-hospital mortality: −0.59 percentage points
[95% CI, −1.96 to 0.78 percentage points]; 30-day mortality: −1.10 percentage points [95% CI, −2.74
to 0.54 percentage points]). Among non-HCA hospitals, LOS among patients admitted with COPD
exacerbation was lower after acquisition (difference, −4.29%; 95% CI, −8.26% to −0.32%), as was
LOS among patients admitted with CHF (difference, −4.51%; 95% CI, −7.72% to −1.29%) (eFigure 8 in
the Supplement).

Discussion
This cross-sectional study used a difference-in-differences framework to evaluate the quality of care
at PE-owned ACHs relative to ACHs without a history of PE acquisition. The impact of PE acquisition
for case selection and clinical quality at short-term ACHs remains relevant to ongoing policy
discussions aimed at promoting greater value in health care spending. Among Medicare
beneficiaries, PE acquisition was associated with consistent improvements in both in-hospital and
30-day mortality among patients with AMI, with comparable overall spending. We found a small but
likely clinically nonmeaningful decrease in LOS among patients admitted with COPD exacerbation
and no difference in 30-day spending or 30-day readmission for all 5 conditions studied. We did not
find any evidence of systematic upcoding (ie, submission of diagnostic codes for services more
expensive than those actually provided) or increased intensity in comorbidity coding (ie, more
frequent comorbidity coding and/or submission of higher comorbidity scores) in the postacquisition
period. These findings were largely corroborated by 2 separate robustness assessments, which
included specifications accounting for any unobserved variation over time or between patients’
socioeconomic status. These findings also persisted in subset analyses that restricted the study
cohort to patients who received treatment in hospital referral regions that had any PE activity, and
the directionality of our results persisted when hospitals were stratified by their participation in the
2006 HCA leveraged buyout.
This study’s findings were inconsistent with the prevailing concerns surrounding PE acquisitions
of health care systems, perhaps highlighting the need for nuanced investigations into the role of
for-profit investments in health care. Regulators may determine that it is not sufficient that for-profit
institutions do no harm; they may instead decide that for-profit owners produce improvements in
value of care, either through better outcomes, lower costs, or both. Proponents of PE acquisition
often assert that revenue generation from target hospitals via taxation is a societal boon, while the
patients they serve may benefit from economies of scale, management expertise, and an incentive to
implement cost-effective care.5,7,29-31 Critics assert that PE firms, unlike other for-profit institutions,
have an inherent incentive to favor short-term returns rather than long-term investments (eg,
information technologies and care redesign) that would otherwise meaningfully improve population
health.29,32 In certain aspects of health care services, the latter view has been bolstered by important
research13,14,33,34 in nursing homes and outpatient clinical practices. Private equity–owned nursing
facilities performed comparably, both in terms of equipment shortages and resident outbreaks,
during the COVID-19 pandemic.14,33 However, cost-cutting measures that led to unsafe staffing ratios
resulted in worse patient outcomes,13 and increased market power has made outpatient practices
more costly for payers.34 Concerns about similar impacts in hospitals are therefore justified. Rather
than focus on PE acquisitions of hospitals as a distinct problem in the health care delivery sector,
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perhaps PE activity might be viewed as a proxy for market failures and payment loopholes that can
be exploited (eg, surprise billing [unexpected charges from out-of-network hospitals or
practitioners], horizontal consolidation, Medicare payment differentials for physician-administered
drugs under Part B, and Medicare Advantage upcoding for benchmark payments [in which enrollees'
potentially comorbid diagnoses are recorded to increase risk-adjusted payments]).35
Our findings with respect to the improvements in AMI care after PE acquisition were consistent
with those of Bruch et al.11 Acute MI may represent an ideal clinical condition for targeted quality
improvement and care redesign efforts by PE ownership because of (1) clear guidelines from the
American College of Cardiology/American Heart Association on the proper management of patients
with AMI,36 (2) a well-understood association between guideline adherence and improved
outcomes,37 and (3) the resource-intensive nature of AMI identification and treatment (eg,
diagnostic imaging, cardiac catheterization, and percutaneous coronary intervention).38
There are several possible explanations for our findings. First, the variation in management
practices and capital allocation across PE firms may result in substantively different operational
changes after acquisition and may therefore have variable consequences for outcomes. Another
explanation may be that all short-term ACHs, PE-acquired or not, are subject to the same regulatory
oversight, accreditation, and quality reporting environment.39 Although PE ownership has been
associated with operational changes,40 it is possible that extant regulatory tolerance for adverse
outcomes prevents drastic cost-cutting measures that result in worse clinical care. At the same time,
there may not be clear avenues for quality improvement in the 4 other medical conditions examined
in the present study. Quality measures for those conditions have several benchmarking approaches
that are not as universally accepted or as easily identifiable in Medicare claims (eg, oxygen
assessment, antimicrobial timing, and appropriate initial antimicrobial selection for pneumonia).41,42
Within the broader literature examining hospital for-profit conversions and their association with
clinical outcomes, our results were also consistent with work by Joynt et al,32 which found no
difference in 30-day risk-adjusted mortality rates and process quality factors associated with AMI,
CHF, and pneumonia across 237 hospitals that converted to for-profit status between 2003
and 2010.

Limitations
This study has several limitations. First, we consider all PE acquisitions to be the same type of
exposure. Although PE firms structure their investments in different ways, we focused on leveraged
buyouts in this study because they are the most common type, and this focus allowed us to avoid
confounding in our analysis that could have occurred by including other deal structures. However,
the amount of debt burden passed on to acquired hospitals by PE firms (ie, the financial obligation
resulting from the deal that has implications for the extent of cost-cutting or revenue increases
required to remain solvent) varies and is often not accessible in the public domain. Moreover,
oversight by state regulators and overall investment practices of each firm may vary, which could
result in nonuniform consequences for each acquisition.
Second, although we consider a broad set of medical conditions and quality measures, we are
unable to capture all dimensions of care quality.43 Third, a difference-in-differences analysis in which
the treatment exposure is a nonrandom event (ie, PE acquisition) may be subject to selection bias.43
Cross-sectional analyses of PE-owned hospitals have revealed that PE firms have lower staffing levels
for a standard measure of patient burden.44 We posit that the nature of nonelective admissions
renders our findings less subject to patient selection or practitioner-related discrimination; future
studies can further assess these differences in the likelihood of acquisition to estimate the impact of
PE acquisition for changes in elective admissions.45
Fourth, our study was conducted entirely among Medicare beneficiaries; although subtle shifts
in the total proportion of Medicare patients may be observable, profit-seeking via changes in patient
access (ie, guiding Medicare or uninsured patients away from inpatient care after PE acquisition or
reducing visits or readmissions among high-risk patients with complex conditions) and the
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consequences of vertical integration (as with the Medicare Advantage program) cannot be easily
measured. Fifth, we examined a short period (3 years) after PE acquisition to avoid overstating or
misassigning the consequences of PE ownership by incorporating data after the inevitable sale (exit)
by the PE firm, which usually occurs at 5 to 7 years after acquisition. Therefore, our findings cannot
be generalized to the longer-term consequences of PE acquisition.46

Conclusions
In this cross-sectional study, acquisition of short-term ACHs by PE firms was associated with modest
improvements in measures of mortality for AMI, with no changes in mortality outcomes across 4
other medical conditions that account for a large proportion of nonelective admissions among
Medicare beneficiaries. These findings challenge the narrative that PE investments in all subsectors
of health care delivery organizations increase health spending and systematically worsen quality. We
believe these findings may further motivate longitudinal research on the consequences of PE
acquisition for physician decision-making, access to care, and health care prices.12 Preferencesensitive elective admissions with clinical management and profitability that are more dependent on
patient selection represent a rich clinical context for this inquiry.
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